SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending as investors discuss Tether's recent $5.7 million investment and broader commitments to Rumble's advertising and cloud services. The community anticipates a potential short squeeze, fueled by high short interest and Tether's increased stake in the company, with some speculating on a year-end rally.

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

Fetch.ai (FET) is trending as traders analyze its potential within the AI sector and speculate on upcoming movements, particularly in relation to Bitcoin's performance. Community members are weighing bullish scenarios and potential breakout points, while also considering recent news and technical analysis to gauge entry and exit points. Discussions also include perspectives on Fetch.ai's long-term potential in the decentralized AI space.

mF International Ltd. is a holding company, which engages in the development and provision of financial trading solutions through its subsidiary. It offers real-time mission critical forex, bullion and commodities trading platform solutions, financial value-added services, mobile applications, and financial information for brokers and institutional clients via internet or platform as software as a service. The company was founded by Tai Wai Lam and Chi Weng Tam on June 15, 2022, and is headquartered in Hong Kong.

mF International Ltd - Ordinary Shares - Class A

mF International Ltd

mF International ($MFI) is trending due to a recently announced private placement of $500 million to launch a digital asset treasury strategy, sparking high trading volume and price volatility. Community members are debating the implications of this move, with some anticipating a potential short squeeze while others caution about the risks associated with pump-and-dump schemes often seen with Hong Kong-based companies. The discussions also involve comparisons to other stocks and speculation about future price movements, reflecting a divided sentiment among investors.

Pump Mind Virus is a Pure Meme with a long term vision. We are building for the future while making no promises about the present. The project aims to bring the spirit of community memes back to the Solana ecosystem. We do that with engaging content and memes. Culture through community. Viral spread by word of mouth.  And most importantly, by not using the fake hype machine that has come to dominate the meme coin landscape.

PumpMindVirus

PumpMindVirus ($PMV) is trending as the community rallies around its meme-driven culture and infectious theme on the Solana blockchain. Discussions highlight the coin's potential for growth and strong community engagement, with many noting its connection to the $PUMP ecosystem. The community emphasizes a fun, meme-focused approach, aiming to spread the "infection" and build a strong presence.

Intuition is the L2 for trusted data, and the world's first token-curated graph—allowing people and machines to get the information they need, when they need it, from the sources they trust. With Intuition, you can put your 'intuition' to work—transforming your thoughts, opinions, and experiences into fuel for personalized AI, recommendations, and ads that truly understand you. You fully control your digital identity and data—the most valuable resources of the digital age—enabling you to fully leverage their value while unlocking and democratizing trillions in economic potential. Bring your social graphs, preferences, and 'intuition' with you wherever you go. No more rebuilding your profile and connections from scratch on every new platform—create and curate a universal, portable identity and context that allows applications and AI across the web to understand you instantly. And as you contribute, you’re not just improving your own experience—you’re enhancing the web for everyone who follows and trusts your perspective.

Trust Community Token

Trust Community Token ($TRUST) is garnering attention, with some users citing its recent listing on Coinbase and potential for high-volume swings. The community is discussing the token's fundamentals, including its tokenomics and development plans, while also pointing out chart discrepancies. Others express concerns, with some users reporting issues with purchasing and questioning the project's progress.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network ($ZBCN) is trending as the community discusses potential partnerships and its integration with NatPay, which gives Zebec access to real-world payment infrastructure. Bullish sentiment is fueled by the possibility of major exchange listings and the potential for ISO 20022 compliance. However, some traders express concerns about token unlocks and broader market volatility.

Blockchain-on-Blockchain (BOB) is a new blockchain built on top of another blockchain called ICP. It's like a special layer on an existing system. BOB creates a secure digital record book that uses ICP's network for safety. BOB uses a system called 'proof-of-on-chain-work': You deploy your own smart contract (canister) at bob.fun. This program solves math problems (hashes). Main computers (mother nodes) give out these problems. Miners solve the problems and tell the mother node. If correct, the mother node adds a new block to the blockchain. The winning miner gets BOB tokens as a reward.

BOB is gaining attention as a novel token built on the ICP blockchain, with some community members drawing parallels to early Bitcoin and highlighting its limited supply. Discussions revolve around its potential within the ICP ecosystem and speculation about future listings and price appreciation. Some users believe that BOB could outperform ICP and become a key driver of network revenue.

Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. It operates through the following segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the line of branded generic pharmaceuticals manufactured worldwide and marketed and sold outside the United States in emerging markets. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, clinics, physicians' offices, retailers, government agencies, and alternate care testing sites. The Nutritional Products segment caters to the worldwide sales of pediatric and adult nutritional products. The Medical Devices segment includes a broad line of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care and continuous glucose monitoring products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Abbott Laboratories

Abbott is trending due to its planned acquisition of Exact Sciences ($EXAS) for approximately $23 billion, with community discussions focusing on the deal's potential impact on Abbott's cancer diagnostics business and whether a bidding war could emerge. The community is analyzing the strategic rationale and potential synergies, particularly regarding cancer screening technologies. Options traders are actively trading ABT calls and puts, indicating expectations for near-term volatility.

Tenax Therapeutics, Inc. is a pharmaceutical company engaged in the development and commercialization of products for cardiovascular and pulmonary diseases. The company was founded on May 26, 1967 and is headquartered in Chapel Hill, NC.

Tenax Therapeutics Inc

TENX is trending due to high volume and upcoming presentation of Phase 3 data, igniting speculation of a potential squeeze. Community chatter highlights low float, significant institutional ownership, and comparisons to other Steve Cohen-backed stocks like CDTX. Some traders suggest the company may be a takeover target, given its current financial position and potential for FDA approval.

Forum Energy Technologies, Inc. designs, manufactures, and distributes products to the oil and natural gas industry. It operates through the Drilling and Completions and Artificial Lift and Downhole segments. The Drilling and Completions segment designs, manufactures and supplies products and solutions to the drilling, subsea, coiled tubing, well stimulation and intervention markets, including applications in oil and natural gas, renewable energy, defense and communications. The Artificial Lift and Downhole segment designs, manufactures and supplies products and solutions for the artificial lift, production and infrastructure markets. The company was founded in 2005 and is headquartered in Houston, TX.

Forum Energy Technologies Inc

Forum Energy Technologies (FET) is trending amidst community discussion around its cash generation, potential for share buybacks, and debt management strategies. Community members are analyzing the impact of the Variperm acquisition and potential catalysts for future growth. Some traders point to the technical setup while others remain cautious, awaiting further confirmation of the company's financial performance and the potential return of capital to shareholders.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Roth Capital sees potential FDA clearance for the software.</li><li>The FDA may want the company to use a different predicate device, pursue a different regulatory pathway, or provide additional data, the analyst said.&nbsp;</li><li>HeartBeam is now evaluating launching its 3D ECG system, which received FDA clearance in December 2024.</li></ul>Shares of HeartBeam, Inc. (BEAT) slumped 58% on Friday afternoon after the company said that the U.S. Food and Drug Administration refused clearance for its 12-Lead Electrocardiogram (ECG) Synthesis Software for arrhythmia assessment.The medical technology company said that it received a ‘not substantially equivalent’ letter from the FDA. A "Not Substantially Equivalent" (NSE) letter is an official notification from the FDA stating that a new medical device is not considered substantially equivalent to a legally marketed predicate device.The company said that it will be working with the agency to get to a resolution and expressed confidence in its clinical data. Earlier this month, HeartBeam had touted FDA clearance for the software as a major inflection point for the company.The company is now evaluating launching its 3D ECG system which received FDA clearance in December 2024.<h2 class="st-heading-2">Analyst Takeaway</h2>Roth Capital, however, sees potential FDA clearance for the software. The FDA may want the company to use a different predicate device, pursue a different regulatory pathway, or provide additional data, it said.While resolving the pathway for the 12-lead ECG synthesis software, management may decide to roll out the foundational 3D ECG system to concierge medical practices, preventive cardiology clinics, and hospital-at-home programs, the analyst said, as per The Fly.The analyst kept a ‘Buy’ rating on HeartBeam with a $4 price target. The price target represents a potential upside of over 138% from the stock’s closing price on Thursday.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BEAT">BEAT stock</a> rose from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user echoed Roth Capital’s opinion and said that the stock would beat $5 on FDA approval.<stembedurl>https://stocktwits.com/jamestocklover/message/637108009</stembedurl>Another noted that an NSE letter is not the end.<stembedurl>https://stocktwits.com/Rolltide2020/message/637103348</stembedurl>BEAT stock is down by 70% this year and by about 75% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/will-scot-stock-surges-after-baird-upgrade-analyst-calls-q3-a-watershed-quarter/cLPMv4RREfb">WillScot Stock Surges After Baird Upgrade – Analyst Calls Q3 A ‘Watershed Quarter’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

HeartBeam Stock Slumps After FDA Refuses Clearance For ECG Software

The company said it will work with the agency to reach a resolution and expressed confidence in its clinical data.

Equity

<ul class="summary-bullets"><li>Hunterbrook said that while Archer brought a model air taxi to the Dubai Airshow, it remained on the ground in one of the exhibition halls.&nbsp;</li><li>Archer’s rival Joby Aviation flew repeatedly at the Dubai Airshow, Hunterbrook said.</li><li>The report comes on the heels of Joby filing a lawsuit against Archer in California Superior Court in Santa Cruz.</li></ul>Hunterbrook Capital on Friday revealed a short position in air taxi maker Archer Aviation (ACHR) and noted that its flagship Midnight electric air taxi never flew at the 2025 Dubai Airshow.“When that flight never happened — and the event came and went — Archer didn’t publicly acknowledge the cancellation,” Hunterbrook <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://hntrbrk.com/archer/">said</a>.The firm said that while Archer brought a model air taxi to the Dubai Airshow, it remained on the ground in one of the exhibition halls, and the company did not respond to its queries. This is seemingly the second time this year that Archer has canceled a planned public display, Hunterbrook noted, referring to the canceled public flight demonstration scheduled for World Expo 2025 in Osaka, Kansai, Japan. Even then, the company decided to exhibit the aircraft but did not fly it, they said.While Archer did fly the aircraft at the Salinas Air Show in California, the vehicle had a traditional landing instead of a vertical one, Hunterbrook said, citing footage from the event. However, despite the dropped flights, Archer has been issuing promotional press releases in recent weeks, Hunterbrook noted.<h2 class="st-heading-2">Rival Performance</h2>Meanwhile, Archer’s rival Joby Aviation (JOBY) flew repeatedly at the Dubai Airshow, Hunterbrook noted. The company is now planning to begin operations in Dubai in early 2026 and is also advancing aircraft beyond eVTOLs, Hunterbrook said.Joby filed a lawsuit against Archer on Wednesday in California Superior Court in Santa Cruz, alleging that a former Joby employee downloaded internal Joby files before joining Archer. Joby dubbed the act one of “corporate espionage, planned and premeditated.”As per Joby, George Kivork, the firm’s U.S. state and local policy lead, downloaded dozens of files and sent some of the content to his personal email days before he submitted his resignation to join Archer. The air taxi maker further alleged that a real estate partner, which had signed an exclusive agreement with a partner, informed Joby that Archer had approached it with a “more lucrative deal.”However, Archer CEO Adam Goldstein hit back at the lawsuit, saying, “Joby’s accusations are fantasy.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ACHR">ACHR stock</a> stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:624/61;" src="data:image/png;base64,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" alt="ACHR’s Sentiment Meter and Message Volume as of 12:03 p.m. ET on Nov. 21, 2025 | Source: Stocktwits" width="624" height="61"><figcaption>ACHR’s Sentiment Meter and Message Volume as of 12:03 p.m. ET on Nov. 21, 2025 | Source: Stocktwits</figcaption></figure>ACHR stock fell 27% this year but gained about 23% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/telo-stock-jumps-pre-maket-after-early-study-results-show-leukemia-cell-death/cLPMFLqREO1">TELO Stock Jumps Pre-market After Early Study Results Show Leukemia Cell Death</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Archer Aviation logo is displayed on a smartphone screen. (Photo by Cheng Xin/Getty Images)

Hunterbrook Capital Reveals Short Position In eVTOL Maker Archer Aviation

Hunterbrook said that Archer’s Might electric air taxi never flew at the 2025 Dubai Airshow.

<ul><li>Eli Lilly is now the first healthcare company to cross the $1 trillion valuation benchmark.</li><li>LLY stock hit as high as $1,061.17 on Friday before paring back gains.</li><li>The company is now looking forward to the launch of its oral GLP-1 drug, Orforglipron, next year to boost market share.</li></ul> Eli Lilly &amp; Co. (LLY) hit a market capitalization of $1 trillion on Friday after its shares rose as much as 1.7% on optimism surrounding the company’s GLP-1 category of drugs.With the rise, Lilly is now the first healthcare company to cross the $1 trillion valuation benchmark, joining technology companies including Tesla. The stock hit as high as $1,061.17 on Friday before paring back gains and bringing down market valuation to below $1 trillion.The company’s GLP-1 drugs, Zepbound, used for weight loss, and Mounjaro, approved for diabetes treatment, have driven investor appetite and pushed its share price by about 40% this year. In the three months through the end of September, the company reported combined Zepbound and Mounjaro revenue of about $10.1 billion. While Mounjaro revenue increased 109% to $6.52 billion in the quarter, Zepbound revenue increased 185% to $3.59 billion.<h2 class="st-heading-2">Pharma Boom, Pipeline Aid Growth</h2>Overall, pharma stocks have had a good run over the past few months. The S&amp;P 500 pharmaceutical index gained 17% over the last month and by about 31% over the past six months.Earlier this month, Lilly also inked an agreement with the White House, agreeing to lower the prices of its blockbuster drugs in return for a three-year exemption from potential tariffs and access to Medicare patients. The company is also looking forward to the launch of its oral GLP-1 drug, Orforglipron, next year to boost market share.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around LLY stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.<a href="https://stocktwits.com/symbol/LLY">LLY stock</a> rose 37% this year and by 41% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/novo-obesity-drug-patients-granted-compensation-in-denmark-over-rare-eye-disease-linked-to-wegovy-ozempic/cLPMqfwREOY">Novo’s Obesity Drug Patients Granted Compensation In Denmark Over Rare Eye Disease Linked To Wegovy, Ozempic</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

A sign with the company logo sits outside of the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana. (Photo by Scott Olson/Getty Images)

Eli Lilly Joins Tech Players In The $1T Market Capitalization Club

The company’s GLP-1 drugs, Zepbound and Mounjaro, have driven investor appetite and pushed its share price by about 40% this year. 

<ul class="summary-bullets"><li>The authority said it has received 43 claims from patients who believe they developed the condition known as NAION after taking Wegovy or Ozempic.</li><li>Though the agency granted compensation in four claims, it also rejected one, bringing the total number of settled cases to five.</li><li>As per the agency, not all cases automatically qualify for compensation, but instead, each claim will be assessed individually.</li></ul>Four patients taking Novo Nordisk’s (NVO) weight loss drugs have been granted compensation in Denmark after they developed an adverse reaction that affected their eyes.The four claimants will receive a combined 800,000 kroner, though that figure may rise, Danish Patient Compensation <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://patienterstatningen.dk/presse-og-nyheder/nyheder/2025/nov/de-foerste-patienter-faar-erstatning-for-alvorlig-oejensygdom-efter-wegovy-og-ozempic">said</a> on Friday. If it is proved that the eye disease is to blame for the patients not being able to do their jobs to the same extent as before, they will be entitled to compensation for loss of earning capacity, the authority said.<h2 class="st-heading-2">Cases In Question</h2>The authority said it has received 43 claims from patients who believe they developed the condition known as NAION after taking Wegovy or Ozempic.NAION, or non-arteritic anterior ischemic optic neuropathy, is a medical condition causing sudden, painless vision loss due to a lack of blood flow to the optic nerve. There is no cure for the condition, which can cause blurry or worsening vision, reduced color vision, and optic disc swelling.<h2 class="st-heading-2">Compensation Not Guaranteed</h2>Though the agency granted compensation in four claims, it also rejected one, bringing the total number of settled cases to five. According to the agency, not all cases automatically qualify for compensation; each claim will be assessed individually to determine whether compensation is warranted.“NAION is a serious disease that causes permanent and incurable damage to vision. It is also a very complex case to assess because it is a new medicine and the patients are already in the risk group for getting NAION. Our task is to give patients a thorough and well-thought-out decision," director of Patient Compensation, Karen-Inger Bast, said. &nbsp;The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) considers NAION to be a rare side effect of Wegovy, Ozempic, and Rybelsus.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2><a href="https://stocktwits.com/symbol/NVO">NVO shares</a> traded 1% lower on Friday morning at the time of writing. On Stocktwits, retail sentiment around NVO stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.NVO stock is down 45% this year and by about 54% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-etfs-hit-record-outflows-average-investor-now-in-the-red/cLPMoktREOm">Bitcoin ETFs Hit Record Monthly Outflows In November – Average Investor Now in the Red, Says Analyst</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. 

Novo’s Obesity Drug Patients Granted Compensation In Denmark Over Rare Eye Disease Linked To Wegovy, Ozempic

The four claimants will receive a combined 800,000 kroner, though that figure may rise, Danish Patient Compensation said on Friday.

<ul class="summary-bullets"><li>After about 10 months of starting treatment with Adzynma, the presence of neutralizing antibodies was identified in the patient who died, the FDA said.&nbsp;</li><li>The FDA is now investigating the risk of development of neutralizing antibodies with serious, including life-threatening or fatal, outcomes following treatment with Adzynma.</li><li>The agency noted that neutralizing antibodies were not reported in clinical trials.</li></ul>The U.S. Food and Drug Administration (FDA) said on Friday that it is investigating the death of a patient treated with Adzynma.Adzynma, a man-made enzyme therapy manufactured by Takeda Pharmaceuticals (TAK), is approved for adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP), also known as Upshaw-Schulman syndrome. It is a rare inherited disorder characterized by a severe deficiency of the ADAMTS13 enzyme.The death of a pediatric cTTP patient appears to be related to Adzynma, the FDA <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-investigating-death-due-neutralizing-antibodies-adamts13-following-adzynma-treatment-congenital">said</a>.<h2 class="st-heading-2">Findings And Further Probe</h2>Before starting Adzynma treatment, the patient had severe allergic reactions to fresh frozen plasma, the FDA noted. After about 10 months of starting treatment with Adzynma, the presence of neutralizing antibodies was identified.However, the agency also noted that current assays cannot differentiate the neutralizing antibodies to man-made enzyme therapy from the neutralizing antibodies to the body’s own enzymes. The agency also added that it has received other reports of neutralizing antibodies in patients treated with the drug since approval.The FDA is now investigating the risk of development of neutralizing antibodies with serious, including life-threatening or fatal, outcomes following treatment with Adzynma. The agency noted that neutralizing antibodies were not reported in clinical trials and that the current labeling does not include the risk of serious and fatal outcomes.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around TAK stayed within the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.<a href="https://stocktwits.com/symbol/TAK">TAK stock</a> has gained 8% this year and about 7% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/novo-obesity-drug-patients-granted-compensation-in-denmark-over-rare-eye-disease-linked-to-wegovy-ozempic/cLPMqfwREOY">Novo’s Obesity Drug Patients Granted Compensation In Denmark Over Rare Eye Disease Linked To Wegovy, Ozempic</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Takeda Pharmaceutical Company, building exterior with company sign, 500 Kendall Street, Cambridge, Massachusetts, USA. (Photo by: Plexi Images/GHI/UCG/Universal Images Group via Getty Images)

Takeda Pharmaceuticals’ Genetic Disease Therapy Under FDA Probe After Pediatric Patient Dies

 The death of a pediatric congenital thrombotic thrombocytopenic purpura patient appears to be related to Adzynma, the FDA said. 

<ul><li>According to Telomir, more than 60,000 new cases of Leukemia are diagnosed each year in the U.S.</li><li>Leukemia cells rely heavily on iron as a fuel source, and Telomir-1 in previous research demonstrated the ability to reduce intracellular iron levels.&nbsp;</li><li>The new findings expand on the experimental drug’s previously reported activity in triple-negative breast, pancreatic, and aggressive prostate cancer models.</li></ul>Telomir Pharmaceuticals, Inc. (TELO) said on Friday that its investigational compound Telomir-1 killed aggressive human leukemia (HL60) cells in an in-vitro study.HL60 leukemia cells were treated with Telomir-1, which produced a clear, dose-dependent reduction in viable leukemia cells, indicating strong activity, the company said.Leukemia is a cancer of the blood and bone marrow defined by the uncontrolled growth of abnormal white blood cells.<a href="https://stocktwits.com/symbol/TELO">TELO shares</a> rose 8% at the time of writing.<h2 class="st-heading-2">New Findings</h2>According to Telomir, more than 60,000 new cases of Leukemia are diagnosed each year in the U.S. Leukemia cells rely heavily on iron as a fuel source, and Telomir-1 in previous research demonstrated the ability to reduce intracellular iron levels."The potency observed in HL60 leukemia cells is consistent with the broader biological patterns we have seen throughout Telomir's research…These findings support our scientific framework for evaluating Telomir-1 and inform the ongoing advancement of our overall oncology research program," the company’s chief scientific advisor, Itzchak Angel,<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://telomirpharma.com/#"> said</a>.The new findings expand on the experimental drug’s previously reported activity in triple-negative breast, pancreatic, and aggressive prostate cancer models. The compound is the company’s lead candidate.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around TELO jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume levels rose from ‘extremely low’ to ‘high’ levels.TELO stock is down 66% this year and by 69% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/google-ai-infra-chief-must-double-ai-compute-twice-a-year/cLPMFWiREOK">Google AI Infra Chief Says It Must Double AI Compute Twice A Year To Meet Demand: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Telomir Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

TELO Stock Jumps Pre-market After Early Study Results Show Leukemia Cell Death 

HL60 leukemia cells were treated with Telomir-1, which produced a clear, dose-dependent reduction in viable leukemia cells, indicating strong activity, the company said.

<ul class="summary-bullets"><li>Anaptys alleges that Tesaro violated the terms of the 2014 deal between the two companies.&nbsp;</li><li>The company said that it approached Tesaro to resolve the claims, but Tesaro initiated a lawsuit against it.</li><li>A trial is now anticipated in July 2026, and milestone and royalty payments continue to be due to Anaptys during the proceedings.</li></ul>AnaptysBio, Inc. (ANAB) said on Friday that it has initiated litigation against GSK unit Tesaro, alleging a breach of the terms of the collaboration agreement between the two companies, inked in March 2014. This renewed battle adds to a fraught relationship between the two companies, with a trial now expected in July next year.<a href="https://stocktwits.com/symbol/ANAB">ANAB shares</a> dipped 10% in the pre-market session at the time of writing.<h2 class="st-heading-2">New Legal Fight</h2>Anaptys has<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.anaptysbio.com/news-releases/news-release-details/anaptys-initiates-litigation-against-tesaro-gsk-subsidiary"> requested</a> that the court declare that Anaptys is entitled to all rights and remedies under the collaboration agreement. The company alleged that Tesaro violated exclusivity obligations by participating in past, ongoing, and upcoming governed clinical trials with PD-1 antagonists, a type of immunotherapy, and failed to use commercially reasonable efforts to obtain optimum commercial return for its immunotherapy called Jemperli. A trial is now anticipated in July 2026 and milestone and royalty payments continue to be due to Anaptys during the proceedings.The company said that it approached Tesaro to resolve the claims, but Tesaro initiated a lawsuit against it. Tesaro, in turn, alleges that Anaptys breached the agreement between the two companies. Anaptys said that Tesaro’s claims are entirely without merit and that it intends to pursue all appropriate legal remedies against Tesaro.<h2 class="st-heading-2">Previous Litigation</h2>Anaptys filed a complaint previously against GSK in 2020, alleging that GSK’s planned trial of Zejula in combination with Merck’s Keytruda violated the exclusivity obligations under the 2014 deal.The complaint resulted in a settlement that included a cash payment.<h2 class="st-heading-2">$100M Stock Repurchase Plan</h2>Separately, Anaptys also announced that its Board of Directors has authorized an amended stock repurchase plan under which the company may repurchase up to $100 million of the company’s outstanding common stock. This is in addition to the $6.4 million that remained as of Nov. 20, 2025, under the current $75 million stock repurchase plan.The shares may be repurchased from time to time in open market transactions, and the stock repurchase plan will expire on March 31, 2026, the company said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around ANAB stayed within the ‘neutral’ territory over the past 24 hours while message volume stayed at ‘extremely low’ levels.<figure class="image"><img style="aspect-ratio:584/61;" src="data:image/png;base64,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" width="584" height="61" alt="ANAB’s Sentiment Meter and Message Volume as of 7:05 a.m. ET on Nov. 21, 2025 | Source: Stocktwits"><figcaption>ANAB’s Sentiment Meter and Message Volume as of 7:05 a.m. ET on Nov. 21, 2025 | Source: Stocktwits</figcaption></figure>ANAB stock has nearly tripled this year and gained 78% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/foxconn-to-pour-up-to-5b-into-us-plants-after-striking-servers-deal-with-openai/cLPMZruREOB">Foxconn To Pour Up To $5B Into US Plants After Striking Servers Deal With OpenAI</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration an AnaptysBio logo is displayed on a smartphone screen in Athens, Greece on January 13, 2023. (Photo illustration by Nikolas Kokovlis/NurPhoto via Getty Images)

ANAB Stock Falls After Company Sues GSK Unit Tesaro Again, Claims Fresh Breach Of 2014 Deal

The dispute centers around Tesaro’s participation in PD-1 trials. 

Tesla-Managed Thirty-Party Owned Supercharger Opens In Florida

The supercharger location, comprising eight stalls, is owned by a third party but managed by Tesla.

Esperion’s stock (ESPR) has risen 40.5% so far in 2025. (Representative Image: Getty Images)

Praxis Precision Medicines Stock Drops After Culper Research Reveals Short Position

The firm alleged that Praxis “gamed” the data from its late-stage trial of Ulixacaltamide in essential tremor.

<ul class="summary-bullets"><li>The company said the probe identified issues in its financial reporting and that it had restated its previously issued financial statements.</li><li>PACS now expects core profit for the full year to be in the range of $480 million to $490 million, above an $472.72 million expected by analysts.&nbsp;</li><li>Revenue for the full year is expected to be in the range of $5.25 billion to $5.35 billion.</li></ul>Shares of PACS Group, Inc. (PACS) jumped 53% in the pre-market session on Thursday after the company said that an audit committee had completed its independent investigation into the allegations made by short seller Hindenburg Research in its report in November 2024.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.pacs.com/news-events/press-releases/detail/121/pacs-group-inc-reports-third-quarter-2025-results">said </a>that the recommendations by the committee have been or are being implemented. The company said that the probe identified issues within its financial reporting and restated its previously issued financial statements, including a $46.1 million reduction in the revenue reported for the three-month period ended June 30, 2024.“...today is the start of a new chapter for PACS,” said CEO Jason Murray in a call with analysts on Wednesday while reiterating efforts to build trust with stakeholders.<h2 class="st-heading-2">Outlook For The Year Ahead</h2>The company now expects core profit for the full year to be in the range of $480 million to $490 million, above the $472.72 million expected by analysts, according to data from Fiscal AI.Revenue for the full year is expected to be in the range of $5.25 billion to $5.35 billion, up from an expected $4.6 billion.<h2 class="st-heading-2">Q3 Earnings</h2>The company reported third quarter revenue of $1.34 billion, an increase of 31.0% over prior year, and above an estimated $949.48 million.Core profit for the three months was $131.5 million, above an estimated $85.90 million.PACS Group is a holding company investing in post-acute healthcare facilities. Its units operate 320 care facilities across 17 states.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around PACS stayed within the ‘extremely bullish’ territory over the past 24 hours while message volume remained at ‘extremely high’ levels. However, retail sentiment around PACS hit its highest levels this year on Thursday.<figure class="image"><img style="aspect-ratio:623/60;" src="data:image/png;base64,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" width="623" height="60" alt="PACS’s Sentiment Meter and Message Volume as of 9:15 a.m. ET on Nov. 20, 2025 | Source: Stocktwits"><figcaption>PACS’s Sentiment Meter and Message Volume as of 9:15 a.m. ET on Nov. 20, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/PACS">PACS stock</a> is up by 28% this year and down by about 2% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-urges-china-customers-to-buy-model-y-inventory-as-wait-time-for-custom-orders-stretch-into-2026/cLPAi4CRE9U">Tesla Urges China Customers To Buy Model Y Inventory As Wait Time For Custom Orders Stretch Into 2026</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, a PACS Group company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

PACS Group Stock Soars Premarket On Completion Of Audit Committee Probe, Upbeat Full-Year Guidance

The company said the committee's recommendations have been or are being implemented.